Array Biopharma, Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Array Biopharma, Inc

ARRY 8.660

+3.2%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: GregorioAllegri	1/14/2017 9:44:20 AM
	1 Recommendation Recommended By scaram(o)uche Read Replies (1) of 321

Comparisons: median progress free survival, BRAF positive, in months. ARRY: binimetinib (MEK) + encorafenib (BRAF) 14.8-14.9 ARRY: encorafenib alone (BRAF) 9.2-9.6 GSK to NVS: TAFINLAR (BRAF)(dabrafenib) + MEKINIST (MEK)(trametinib): 9.3-11.4 GSK to NVS: TAFINLAR alone: 5.1-8.8 RHHBY + EXEL: ZELBORAF (vemurafenib)(BRAF) + COTELLIC (cobimetinib)(MEK): 12.3 RHHBY: ZELBORAF alone: 7.2-7.3 Dacarbazine: 2.7 Question: what is the median progress free survival, patients with brain metastases, BRAF positive, in months. TAFINLAR alone was 4.6 mos. Better safety (grade 3/4, less than competition): photosensitivity, secondary non-melanoma skin neoplasms; Safety concerns (elevated over competition, mostly <grade 3): retinal pigment detachment; left ventricular dysfunction. Last two days of stock action: Hot money coming in from former holders of ARIA, a company with comparable drugs and owned to some degree by Sarissa Capital Management (a very successful hedge fund)? Sources: pharma.us.novartis.com gene.com Array presentation, JP Morgan Healthcare Conference, Jan. 9-12, 2017. ga

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next